BACKGROUND: Primary graft dysfunction, formerly termed reperfusion pulmonary edema, is the leading cause of short-term complications after lung transplantation. New evidence shows that alveolar type I epithelial cells play an active role in alveolar fluid transport and are therefore presumed to be critical in the absorption of pulmonary edema. We tested the potential relevance of a novel marker of alveolar type I cell injury, the receptor for advanced glycation end-products (RAGE), to short-term outcomes of lung transplantation. METHODS: The study was a prospective, observational cohort study of 20 patients undergoing single lung, bilateral lung or combined heart-lung transplantation. Plasma biomarkers were measured 4 hours after allograft reperfusion. RESULTS: Higher plasma RAGE levels were associated with a longer duration of mechanical ventilation and longer intensive care unit length of stay, in contrast to markers of alveolar type II cell injury, endothelial injury and acute inflammation. Specifically, for every doubling in plasma RAGE levels, the duration of mechanical ventilation increased on average by 26 hours, adjusting for ischemia time (95% confidence interval [CI] 7.4 to 44.7 hours, p = 0.01). Likewise, for every doubling of plasma RAGE levels, intensive care unit length of stay increased on average by 1.8 days, again adjusting for ischemia time (95% CI 0.13 to 3.45 days p = 0.04). In contrast, the clinical diagnosis of primary graft dysfunction was not as predictive of these short-term outcomes. CONCLUSIONS: Higher levels of plasma RAGE measured shortly after reperfusion predicted poor short-term outcomes from lung transplantation. Elevated plasma RAGE levels may have both pathogenetic and prognostic value in patients after lung transplantation.
BACKGROUND:Primary graft dysfunction, formerly termed reperfusion pulmonary edema, is the leading cause of short-term complications after lung transplantation. New evidence shows that alveolar type I epithelial cells play an active role in alveolar fluid transport and are therefore presumed to be critical in the absorption of pulmonary edema. We tested the potential relevance of a novel marker of alveolar type I cell injury, the receptor for advanced glycation end-products (RAGE), to short-term outcomes of lung transplantation. METHODS: The study was a prospective, observational cohort study of 20 patients undergoing single lung, bilateral lung or combined heart-lung transplantation. Plasma biomarkers were measured 4 hours after allograft reperfusion. RESULTS: Higher plasma RAGE levels were associated with a longer duration of mechanical ventilation and longer intensive care unit length of stay, in contrast to markers of alveolar type II cell injury, endothelial injury and acute inflammation. Specifically, for every doubling in plasma RAGE levels, the duration of mechanical ventilation increased on average by 26 hours, adjusting for ischemia time (95% confidence interval [CI] 7.4 to 44.7 hours, p = 0.01). Likewise, for every doubling of plasma RAGE levels, intensive care unit length of stay increased on average by 1.8 days, again adjusting for ischemia time (95% CI 0.13 to 3.45 days p = 0.04). In contrast, the clinical diagnosis of primary graft dysfunction was not as predictive of these short-term outcomes. CONCLUSIONS: Higher levels of plasma RAGE measured shortly after reperfusion predicted poor short-term outcomes from lung transplantation. Elevated plasma RAGE levels may have both pathogenetic and prognostic value in patients after lung transplantation.
Authors: Birgit Liliensiek; Markus A Weigand; Angelika Bierhaus; Werner Nicklas; Michael Kasper; Stefan Hofer; Jens Plachky; Herman-Josef Gröne; Florian C Kurschus; Ann Marie Schmidt; Shi Du Yan; Eike Martin; Erwin Schleicher; David M Stern; G ünterJ Hämmerling G; Peter P Nawroth; Bernd Arnold Journal: J Clin Invest Date: 2004-06 Impact factor: 14.808
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: Jason D Christie; Nancy Robinson; Lorraine B Ware; Michael Plotnick; Joao De Andrade; Vibha Lama; Aaron Milstone; Jonathan Orens; Ann Weinacker; Ejigayehu Demissie; Scarlett Bellamy; Steven M Kawut Journal: Am J Respir Crit Care Med Date: 2006-10-05 Impact factor: 21.405
Authors: J Brett; A M Schmidt; S D Yan; Y S Zou; E Weidman; D Pinsky; R Nowygrod; M Neeper; C Przysiecki; A Shaw Journal: Am J Pathol Date: 1993-12 Impact factor: 4.307
Authors: Yasuo Sekine; Thomas K Waddell; Andrea Matte-Martyn; Andrew F Pierre; Marc de Perrot; Stefan Fischer; John Marshall; John Granton; Michael A Hutcheon; Shaf Keshavjee Journal: J Heart Lung Transplant Date: 2004-01 Impact factor: 10.247
Authors: Lorraine B Ware; Mark D Eisner; B Taylor Thompson; Polly E Parsons; Michael A Matthay Journal: Am J Respir Crit Care Med Date: 2004-06-16 Impact factor: 21.405
Authors: S M Pham; Y Yoshida; R Aeba; B G Hattler; Y Iwaki; A Zeevi; R L Hardesty; B P Griffith Journal: J Heart Lung Transplant Date: 1992 Nov-Dec Impact factor: 10.247
Authors: Damien J Lapar; Vanessa A Hajzus; Yunge Zhao; Christine L Lau; Brent A French; Irving L Kron; Ashish K Sharma; Victor E Laubach Journal: Am J Respir Cell Mol Biol Date: 2011-10-06 Impact factor: 6.914
Authors: Ashish Agrawal; Michael A Matthay; Kirsten N Kangelaris; John Stein; Jeffrey C Chu; Brandon M Imp; Alfredo Cortez; Jason Abbott; Kathleen D Liu; Carolyn S Calfee Journal: Am J Respir Crit Care Med Date: 2013-04-01 Impact factor: 21.405
Authors: Barbara C S Hamilton; Gabriela R Dincheva; Hanjing Zhuo; Jeffrey A Golden; Marek Brzezinski; Jonathan P Singer; Michael A Matthay; Jasleen Kukreja Journal: Clin Transplant Date: 2018-02-23 Impact factor: 2.863